BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results from its broad hematology program will be presented at the 26^th European Hematology Association 2021 (EHA2021) Virtual Congress being held June 9 – 17, 2021.

“Following key head-to-head data from the positive ALPINE trial interim analysis and the previously announced ASPEN trial, we are thrilled to share additional updates from BRUKINSA’s broad global clinical program at EHA. In these trials, sustained responses with BRUKINSA treatment were observed consistently across multiple indications and patient subgroups, and it was well tolerated in patients, including those with previously treated B-cell malignancies who discontinued other BTK inhibitors due to intolerable adverse events,” said Jane Huang, M.D., Chief Medical Officer, Hematology of BeiGene. “In addition to BRUKINSA, we are pleased to be presenting long-term efficacy results from our anti-PD-1 antibody tislelizumab in classical Hodgkin’s lymphoma, which is approved for use in China. We are also encouraged by the preliminary safety data of our novel investigational Bcl-2 inhibitor and look forward to further evaluating this recently advanced clinical candidate in combination with BRUKINSA for patients with hematologic malignancies.”

To learn more about BeiGene’s research and development and activities around the EHA2021 Virtual Congress, please visit https://beigenemedical.eu.

Promising Head-to-Head and Long-Term Data Support BeiGene’s Aspiration to Improve Patient Outcomes for More Patients with BRUKINSA

Since its first-in-human study in 2014, a broad clinical program for BRUKINSA has provided a growing body of clinical evidence demonstrating its consistent efficacy and tolerability profile across B-cell malignancies, genotypes, and other patient characteristics. To further demonstrate the clinical profile of this molecule that was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity, BeiGene took a bold approach in the development of BRUKINSA, including two large-scale Phase 3 head-to-head trials against the first-generation BTK inhibitor ibrutinib: